Human UGT2B7 catalyzes morphine glucuronidation

Drug Metabolism and Disposition

Volumn 25, Issue 1, 1997, Pages 1-4

  Coffman, Birgit L ^b   Rios, Gladys R ^b   King, Christopher D ^b   Tephly, Thomas R ^a  

^a UNIVERSITY OF IOWA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLUCURONOSYLTRANSFERASE; MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE;

AMINO ACID SEQUENCE; ARTICLE; DRUG GLUCURONIDATION; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME INDUCTION; HUMAN; LIVER MICROSOME METABOLISM; PRIORITY JOURNAL; SEQUENCE HOMOLOGY;

CELL LINE; CLONING, MOLECULAR; DNA, COMPLEMENTARY; GENE EXPRESSION; GLUCURONOSYLTRANSFERASE; HUMANS; ISOENZYMES; KINETICS; MICROSOMES, LIVER; MORPHINE; SEQUENCE ANALYSIS; SUBSTRATE SPECIFICITY;

EID: 0031022419     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. D. J. Clarke and B. Burchell: The uridine diphosphate glucuronosyltransferase multigene family: function and regulation. In "Handbook of Experimental Pharmacology, Volume 112. Conjugation-Deconjugation Reactions in Drug Metabolism and Toxicity" (F.C. Kauffman, ed.), pp. 3-43. Springer-Verlag, Berlin, 1994.
2. J. K. Ritter, F. Chen, Y. Y. Sheen, H. M. Tran, S. Kimura, M. T. Yeatman, and I. S. Owens: A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isoenzymes with identical carboxyl termini. J. Biol. Chem. 267, 3257-3261 (1992).
3. B. Burchell, C. H. Brierley, and D. Rance: Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation. Life Sci. 57, 1819-1831 (1995).
4. G. Monaghan, S. Povey, B. Burchell, and M. Boxer: Localization of a bile acid UDP-glucuronosyltransferase gene (UGT2B4) to chromosome 4 using the polymerase chain reaction. Genomics 13, 908-909 (1992).
5. G. Monaghan, D. J. Clarke, S. Povey, C. G. See, M. Boxer, and B. Burchell: Isolation of a human YAC contig encompassing a cluster of UGT2 genes and its regional localization to chromosome 4q3. Genomics 23, 496-499 (1994).
6. K. Oguri, S. Ida, H. Yoshimura, and H. Tsukamoto: Metabolism of drugs LXIX. Studies on the urinary metabolites of morphine in several mammalian species. Chem. Pharm. Bull. 18, 2414-2419 (1970).
7. S. Y. Yeh, G. W. Gorodetsky, and H. A. Krebs: Isolation and identification of morphine-3 and 6-glucuronides, morphine 3,6 diglucuronide, morphine 3-ethereal sulfate, normorphine and normorphine 6-glucuronide as morphine metabolites in humans. J. Pharm. Sci. 66, 1288-1293 (1977).
8. E. del Villar, E. Sanchez, A. P. Autor, and T. R. Tephly: Morphine metabolism. III. Solubilization and separation of morphine and p-nitrophenol uridine-diphosphateglucuronosyltransferase. Mol. Pharmacol. 11, 236-240 (1975).
9. J. F. Puig and T. R. Tephly: Isolation and purification of rat liver morphine UDP-glucuronosyltransferase. Mol. Pharmacol. 30, 558-565 (1986).
10. B. L. Coffman, G. R. Rios, and T. R. Tephly: Purification and properties of two rat liver phenobarbital-inducible UDP-glucuronosyltransferases that catalyze the glucuronidation of opioids. Drug Metab. Disp. 24, 329-333 (1996).
11. P. J. Bosma, J. Seppen, B. Goldhoorn, C. Bakker, R. P. J. Oude Elferink, J. R. Chowdhury, N. R. Chowdhury, and P. L. M. Jansen: Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. J. Biol. Chem. 269, 17960-17964 (1994).
12. C. D. King, M. D. Green, B. L. Coffman, I. S. Owens, W. P. Bishop, and T. R. Tephly: The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-glucuronosyltransferases 1.1. Arch. Biochem. Biophys. 332, 92-100 (1996).
13. J. O. Miners, K. J. Lillywhite, and D. J. Birkett: In vitro evidence for the involvement of at least two forms of human liver UDP-glucuronosyltransferase in morphine 3-glucuronidation. Biochem. Pharmacol. 37, 2839-2845 (1988).
14. A. Wahlström, G. M. Pacifici, B. LindstrOm, L. Hammar, and A. Rane: Human liver morphine UDP-glucuronyltransferase enantioselectivity and inhibition by opioid congeners and oxazepam. Br. J. Pharmacol. 94, 864-870 (1988).
15. C. Jin, J. O. Miners, K. J. Lillywhite, and P. I. Mackenzie: Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxyl acid-containing drugs. J. Pharmacol. Exp. Ther. 264, 475-479 (1993).
16. C. A. Chen and H. Okayama: Calcium phosphate-mediated gene transfer: a highly efficient system for stably transforming cells with plasmid DNA. Biotechniques 6, 632-638 (1988).
17. M. D. Green, E. M. Oturu, and T. R. Tephly: Stable expression of a human liver UDP-glucuronosyltransferase (UGT2B15) with activity toward steroid and xenobiotic substrates. Drug Metab. Dispos. 22, 799-805 (1994).
18. E. Battaglia, C. Senay, S. Fournel-Gigleux, R. Herber, G. Siest, and J. Magdalou: The chemical modification of human liver UDP-glucuronosyltransferase UGT1*6 reveals the involvement of a carboxyl group in catalysis. FEBS Lett. 346, 146-150 (1994).
19. Q. Yue, C. von Bahr, I. Odar-Cederlof, and J. Sawe: Glucuronidation of codeine and morphine in human liver and kidney microsomes: effect of inhibition. Pharmacol. Toxicol. 66, 221-226 (1990).
20. M. Pritchard, S. Fournel-Gigleux, G. Siest, P. Mackenzie, and J. Magdalou: A recombinant phenobarbital-inducible rat liver (UDP-glucuronosyltransferase 2B1) stably expressed in V79 cells catalyzes the glucuronidation of morphine, phenols and carboxylic acids. Mol. Pharmacol. 45, 42-50 (1994).
21. J. K. Ritter, Y. Y. Sheen, and I. S. Owens: Cloning and expression of human liver UDP-glucuronosyltransferase in COS-1 cells. J. Biol. Chem. 265, 7900-7906 (1989).
22. A. Rane, J. Sawe, G. M. Pacifici, J.-O. Svensson, and K. Lager: Regios-elective glucuronidation of morphine and interactions with benzodiazepines in human liver. Adv. Pain Res. Ther. 8, 57-64 (1986).
23. R. Osborne, S. Joel, D. Trew, and M. Slevin: Morphine and metabolite behaviour after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin. Pharmacol. Ther. 47, 12-19 (1990).
24. Y. Hashigushi, P. E. Molina, and N. N. Abumrad: Morphine-3-glucuronide: hyperglycemic and neuroendocrine potentiating effects. Brain Res. 694, 13-20 (1995).
25. M. Patel, B. K. Tang, and W. Kalow: (S) oxazepam is inhibited by ketoprofen and other substrates of UGT2B7. Pharmacogenetics 5, 43-49 (1995).
26. M. Patel, B. K. Tang, D. M. Grant, and W. Kalow: Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepam. Pharmacogenetics 5, 287-297 (1995).
27. A. Cowan and J. W. Lewis (eds.): "Buprenorphine: Combating Drug Abuse with a Unique Opioid." Wiley-Liss, New York, 1995.
28. D. Davidson, R. Swift, and E. Fitz: Naltrexone increases the latency to drink alcohol in the social drinkers. Alcohol. Clin. Exp. Res. 20, 732-739 (1996).